New drug combo aims to slow advanced breast cancer
NCT ID NCT07037199
First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This study tests a two-step treatment plan for people with a certain type of advanced breast cancer (HR+/HER2-low). First, they receive a drug called trastuzumab rezetecan for several months. Then, they switch to a combination of a CDK4/6 inhibitor and hormone therapy. The goal is to see if this sequence helps keep the cancer from growing longer. About 45 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.